The Winter Olympics and Renal Denervation have two things in common: Firstly they are both supposed to do some good for humanity…one to inspire it, one to cure it. Secondly they both involve a degree of rapid downhill progress. This week’s editorial argues that in the best interest of the patient community they purport to serve, the renal denervation players are right to take a breather and consider how they are going to handle the situation brought about by weak clinical data in the Medtronic Symplicity HTN-3 study. Most importantly, they should be aiming at truly understanding the impact of the therapy on patients with more and better studies before claiming a revolution in treatment of drug resistant hypertensive patients.
Find it here.